A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.

@article{Saracco2001AR4,
  title={A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.},
  author={Giorgio Saracco and Alessia Ciancio and Alda Olivero and Antonina Smedile and Luigi Roffi and Guido Croce and Cosimo Colletta and Giuseppe Cariti and Massimo Andreoni and Alberto Biglino and Guido Calleri and Graziela Maggi and Gian Franco Tappero and Pier Giulio Orsi and Natalia L Terreni and Antonio Macor and Anteo di Napoli and Elisabetta Rinaldi and Giovannino Ciccone and Mario Rizzetto},
  journal={Hepatology},
  year={2001},
  volume={34 1},
  pages={133-8}
}
To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy. Group 1 (n = 139) received 3 million units (MU) IFN-alpha2b 3 times a week (t.i.w.) plus ribavirin 1,000 mg/d for 12 months; group 2 (n = 162) received 5 MU t.i.w. plus ribavirin for 12… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Interferon-α-2b Plus Ribavirin

View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…